Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Brian W Dymock"'
Autor:
Felicity Sartain, Andrea K. Viecelli, Margaret Veitch, Michael E. Franklin, Brian W. Dymock, James W. Wells, Scott B. Campbell
Publikováno v:
Transplant International, Vol 37 (2024)
Solid organ transplant recipients are at an increased risk of developing skin cancers due to chronic immunosuppression, particularly with calcineurin inhibitors. Tacrolimus is the most prescribed calcineurin inhibitor in this patient cohort, and unde
Externí odkaz:
https://doaj.org/article/b708d85e12904f45a58f0c4354627a2c
Autor:
H Peter Soyer, Ian H Frazer, Andrew Harvey, Margaret Veitch, Kimberly Beaumont, Rebecca Pouwer, Hui Yi Chew, Scott Campbell, Brian W Dymock, Terrie-Anne Cock, James W Wells
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Immunosuppressive drugs such as tacrolimus have revolutionized our ability to transplant organs between individuals. Tacrolimus acts systemically to suppress the activity of T-cells within and around transplanted organs. However, tacrolimu
Externí odkaz:
https://doaj.org/article/79389749edd145c185881ce7f7b6a0b1
Autor:
Mayumi Kitagawa, Pei-Ju Liao, Kyung Hee Lee, Jasmine Wong, See Cheng Shang, Noriaki Minami, Oltea Sampetrean, Hideyuki Saya, Dai Lingyun, Nayana Prabhu, Go Ka Diam, Radoslaw Sobota, Andreas Larsson, Pär Nordlund, Frank McCormick, Sujoy Ghosh, David M. Epstein, Brian W. Dymock, Sang Hyun Lee
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
The Ras/Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways are essential for cancer cell survival. Here, the authors describes a molecule a131 with dual-inhibitory properties, which targets PI5P4K and mitosis, and it is involved in Ras/Raf/MEK/ERK and
Externí odkaz:
https://doaj.org/article/6b5dccbe0c124c53b9c0ce7603c0b8e2
Autor:
Zheng-Wei Lee, Xin-Yi Teo, Zhi J. Song, Dawn S. Nin, Wisna Novera, Bok A. Choo, Brian W. Dymock, Philip K. Moore, Ruby Y.-J. Huang, Lih-Wen Deng
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2017)
Slow and continuous release of H2S by GYY4137 has previously been demonstrated to kill cancer cells by increasing glycolysis and impairing anion exchanger and sodium/proton exchanger activity. This action is specific for cancer cells. The resulting l
Externí odkaz:
https://doaj.org/article/f4a5263f285b4a769eeb00d545b4e266
Publikováno v:
Frontiers in Microbiology, Vol 8 (2017)
Mycobacteria harbor two main degradative proteolytic machineries, the caseinolytic protease ClpP1P2 and a proteasome. We recently showed that Bortezomib inhibits ClpP1P2 and exhibits whole cell activity against Mycobacterium tuberculosis. Bortezomib,
Externí odkaz:
https://doaj.org/article/c51e868a4b1a4fcdb6353893f7488139
Autor:
Rajamani Lakshminarayanan, Norrapat Shih, Gavin S. Dawe, Subhi Marwari, Anders Poulsen, Brian W. Dymock, R. Manjunatha Kini, Charles W. Johannes
Publikováno v:
British Journal of Pharmacology
Background and purpose Depression and anxiety are common causes of disability, and innovative tools and potential pharmacological targets are actively sought for prevention and treatment. Therapeutic strategies targeting the relaxin-3 peptide or its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e7876c9fbeb9e10bda86907bbcf1a91
https://doi.org/10.1111/bph.14774
https://doi.org/10.1111/bph.14774
Autor:
Yu-yi Chu-Farseeva, Anders Poulsen, Jeffrey J.Y. Yen, Brian W. Dymock, Nurulhuda Mustafa, Wee Joo Chng, Eng Chong Tan
Publikováno v:
European Journal of Medicinal Chemistry. 158:593-619
Specifically blocking more than one oncogenic pathway simultaneously in a cancer cell with a combination of different drugs is the mainstay of the majority of cancer treatments. Being able to do this via two targeted pathways without inducing side ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::903f9c48229ad4612756d30f721502c2
https://doi.org/10.1016/j.ejmech.2018.09.024
https://doi.org/10.1016/j.ejmech.2018.09.024
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 28:2636-2640
Inhibition of more than one pathway in a cancer cell with a single molecule could result in better therapies with less complex dosing regimens. In this work multi-component ligands have been prepared by joining together key pharmacophores of two diff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f67e02fd89691fcd2d3be8347e98fb13
https://doi.org/10.1016/j.bmcl.2018.06.037
https://doi.org/10.1016/j.bmcl.2018.06.037
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 28:1357-1362
Inhibition of multiple signaling pathways in a cancer cell with a single molecule could result in better therapies that are simpler to administer. Efficacy may be achieved with reduced potency against individual targets if there is synergy through mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a519072adb538fb25616fac50a323c
https://doi.org/10.1016/j.bmcl.2018.03.009
https://doi.org/10.1016/j.bmcl.2018.03.009
Autor:
Radoslaw M. Sobota, Pei-Ju Liao, Frank McCormick, Mayumi Kitagawa, Noriaki Minami, Nayana Prabhu, Brian W. Dymock, Sang Hyun Lee, Oltea Sampetrean, Go Ka Diam, David M. Epstein, Kyunghee Lee, Dai Lingyun, Jasmine Wong, Pär Nordlund, Sujoy Ghosh, Hideyuki Saya, Andreas Larsson, See Cheng Shang
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Nature Communications
Nature communications, vol 8, iss 1
Nature Communications
Nature communications, vol 8, iss 1
Achieving robust cancer-specific lethality is the ultimate clinical goal. Here, we identify a compound with dual-inhibitory properties, named a131, that selectively kills cancer cells, while protecting normal cells. Through an unbiased CETSA screen,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c35166a5a0b5958b8c4cba9fbbeb7b4
https://doaj.org/article/6b5dccbe0c124c53b9c0ce7603c0b8e2
https://doaj.org/article/6b5dccbe0c124c53b9c0ce7603c0b8e2